AVDL
AVADEL PHARMACEUTICALS PLC
—
Biotech & Drug Discovery
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 earnings_calendar
AVDL Q2 2026 Earnings Scheduled — 2026-08-05
Feb 12, 2026 Insider
Divis Gregory J disposed of 600,000 shares
Chief Executive Officer
Feb 12, 2026 Insider
Amin Naseem disposed of 11,000 shares
Director
Feb 12, 2026 Insider
Divis Gregory J disposed of 10,000 shares
Chief Executive Officer @ $21.00 ($210.0K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Nov 20, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Nov 7, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Oct 28, 2025 | UBS | DOWNGRADE | Neutral | 55% |
| Oct 23, 2025 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Oct 23, 2025 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Oct 22, 2025 | Jefferies | DOWNGRADE | Hold | 53% |
| Oct 22, 2025 | Needham | DOWNGRADE | Hold | 50% |
| Sep 5, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 3, 2025 | Wells Fargo | INITIATE | Equal-Weight | 54% |
| Aug 21, 2025 | UBS | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| May 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Apr 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Mar 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Feb 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% | |
| Jan 1, 2026 | 2 | 4 | 10 | 0 | 0 | 38% |
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 5, 2026
earnings_calendar
AVDL Q2 2026 Earnings Scheduled — 2026-08-05
Jun 11, 2026
Clinical Trial
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Phase Phase 3 — COMPLETED
Jun 11, 2026
clinical_trial_readout
Results Pending: FT218 (Phase 3) — Completed 78d ago
Trial: Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) Sponsor: Avadel Phase: Phase 3 | Completed: 2026-03-25 Conditions: Idiopathi
May 11, 2026
clinical_trial_readout
Results Pending: FT218 (Phase 3) — Completed 47d ago
Trial: Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) Sponsor: Avadel Phase: Phase 3 | Completed: 2026-03-25 Conditions: Idiopathi
May 5, 2026
earnings_calendar
AVDL Q1 2026 Earnings Scheduled — 2026-05-05
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 600,000 | — | — |
| Feb 12, 2026 | Amin Naseem | Director | D | 11,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 10,000 | $21.00 | $210.0K |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 100,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 50,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 400,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 500,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 310,000 | — | — |
| Feb 12, 2026 | Divis Gregory J | Chief Executive Officer | D | 350,000 | — | — |
| Feb 12, 2026 | Ende Eric J | Director | D | 60,000 | — | — |